SOUTH SAN FRANCISCO, CA, SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions, announced a $100 million Series C financing led by Novo Holdings.
SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions, announced a $100 million Series C financing. Led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, BSQUARED Capital, and existing investors, the financing will support the advancement of SiteOne's portfolio of selective, small molecule ion channel modulators for the treatment of sensory hyperexcitability disorders through human clinical proof of concept.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
